Seer, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:26 pm EST
Share
Seer, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 1.43 million compared to USD 1.32 million a year ago. Revenue was USD 4.16 million compared to USD 3.96 million a year ago. Net loss was USD 21.09 million compared to USD 23.98 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.38 a year ago.
For the nine months, sales was USD 4.09 million compared to USD 3.49 million a year ago. Revenue was USD 12.22 million compared to USD 10.89 million a year ago. Net loss was USD 68.48 million compared to USD 70.44 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 1.13 a year ago.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
